Abstract
We studied the pharmacokinetics of intramuscular ceforanide in 46 infants, children, and adolescents, ranging in age from 1 month to 17 years. After the subjects were given 20-mg doses of ceforanide per kg, the mean peak plasma concentration was 56.3 microgram/ml (range, 27.0 to 95.0), the mean 8-h level was 5.9 microgram/ml (range, 1.5 to 13.5), and the mean 12-h level was 1.5 microgram/ml (range, 0.2 to 4.2). Ceforanide half-life varied with the ages of the patients: in 1- to 2-year-old children, in half-life was significantly shorter (1.5 h) than in younger or older children. Plasma concentrations at 8 and 12 h after a dose were lowest in 1- to 2-year-old children. There was no relationship between the area under the curve, the volume of distribution, or the body clearance of ceforanide to the ages of the patients. Within 6 h of administration of the drug, a mean of 77.5% of a dose was excreted in urine, and at the end of 12 h, virtually all (93.9%) of the administered dose was recovered in urine samples. The administration of ceforanide every 12 h did not result in drug accumulation. A dose of 20 mg of ceforanide per kg every 12 h is recommended for most pediatric patients. Dosage recommendations for 1- to 2 year-old children are presented.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Done A. K., Cohen S. N., Strebel L. Pediatric clinical pharmacology and the "therapeutic orphan". Annu Rev Pharmacol Toxicol. 1977;17:561–573. doi: 10.1146/annurev.pa.17.040177.003021. [DOI] [PubMed] [Google Scholar]
- Jovanovich J. F., Saravolatz L. D., Burch K., Pohlod D. J. Failure of probenecid to alter the pharmacokinetics of ceforanide. Antimicrob Agents Chemother. 1981 Oct;20(4):530–532. doi: 10.1128/aac.20.4.530. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lee F. H., Pfeffer M., Van Harken D. R., Smyth R. D., Hottendorf G. H. Comparative pharmacokinetics of ceforanide (BL-S786R) and cefazolin in laboratory animals and humans. Antimicrob Agents Chemother. 1980 Feb;17(2):188–192. doi: 10.1128/aac.17.2.188. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Leitner F., Misiek M., Pursiano T. A., Buck R. E., Chisholm D. R., DeRegis R. G., Tsai Y. H., Price K. E. Laboratory evaluation of BL-S786, a cephalosporin with broad-spectrum antibacterial activity. Antimicrob Agents Chemother. 1976 Sep;10(3):426–435. doi: 10.1128/aac.10.3.426. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Pfeffer M., Gaver R. C., Van Harken D. R. Human pharmacokinetics of a new braod-spectrum parenteral cephalosporin antibiotic, ceforanide. J Pharm Sci. 1980 Apr;69(4):398–403. doi: 10.1002/jps.2600690409. [DOI] [PubMed] [Google Scholar]
- Rane A., Wilson J. T. Clinical pharmacokinetics in infants and children. Clin Pharmacokinet. 1976;1(1):2–24. doi: 10.2165/00003088-197601010-00002. [DOI] [PubMed] [Google Scholar]
- Smyth R. D., Pfeffer M., Glick A., Van Harken D. R., Hottendorf G. H. Clinical pharmacokinetics and safety of high doses of ceforanide (BL-S786R) and cefazolin. Antimicrob Agents Chemother. 1979 Nov;16(5):615–621. doi: 10.1128/aac.16.5.615. [DOI] [PMC free article] [PubMed] [Google Scholar]
- WINBERG J. The 24-hour true endogenous creatinine clearance in infants and children without renal disease. Acta Paediatr. 1959 Sep;48:443–452. [PubMed] [Google Scholar]